🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07106021
Active, not recruiting Phase 1/2

A Study to Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients With Idiopathic Parkinson's Disease

NCT07106021 · tracked via the Priya Life Science USA tracker
Sponsor
Kenai Therapeutics
Phase
Phase 1/2
Started
2025-07-17
Last updated
2026-07-27

Condition(s) studied

Idiopathic Parkinson´s DiseaseParkinson's Disease

Investigational drug(s) / intervention(s)

RNDP-001Syringe Front-Loading Device

RNDP-001: Stem cells

Syringe Front-Loading Device: Delivers the stem cells

Study summary

This clinical trial is designed to test the safety and tolerability of the study intervention, RNDP-001, which will be implanted into the brain of study participants during a surgical procedure.

Eligibility

Sex
ALL
Min age
45 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of idiopathic Parkinson's disease consistent with the Movement Disorders Society Clinical Criteria * Age 45 to 75 * Medically stable to undergo a surgical procedure Exclusion Criteria: * Known Parkinson's disease gene mutation or variant * Previous infusion therapy or surgery for Parkinson's disease * History of allergic reaction or intolerance to an immunotherapeutic agent * Contraindication to MRI * Clinically significant medical conditions likely to interfere with the surgical procedure or study assessments

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
University of Arizona Tucson Arizona
Keck Medical Center of University of Southern California Los Angeles California
The Ohio State University Wexner Medical Center Columbus Ohio
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07106021 on ClinicalTrials.gov ↗ ← All trials in the USA